Ticker

No recent analyst price targets found for LMLLF.

Latest News for LMLLF

PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

Independent research identified cepharanthine as a potential Hantavirus entry inhibitor, supporting further evaluation of Sairiyo's patented, orally bioavailable PD-001 cepharanthine formulation for Hantavirus Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company, today announced that Sairiyo…

Newsfile Corp • May 13, 2026
PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

Independent research identified cepharanthine as a potential Hantavirus entry inhibitor, supporting evaluation of Sairiyo's patented, orally bioavailable PD-001 formulation of cepharanthine for Hantavirus Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and…

Newsfile Corp • May 13, 2026

🧮 Earnings Move Analyzer

Insider Trading

No insider trades found for LMLLF.

No Senate trades found for LMLLF.

No House trades found for LMLLF.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top